Welcome to our dedicated page for Frontage Hldgs news (Ticker: FTHCY), a resource for investors and traders seeking the latest updates and insights on Frontage Hldgs stock.
The news page for Frontage Holdings Corporation (FTHCY) highlights announcements and developments related to its global Contract Research Organization and CRDMO activities. Frontage and its subsidiaries, including Frontage Laboratories, Inc., regularly release updates on facility expansions, collaborations, acquisitions, leadership changes, and recognition within the pharmaceutical and biotechnology services industry.
Readers can find coverage of facility launches and capacity expansions, such as the opening of a CRDMO GMP facility at the company’s campus in Exton, Pennsylvania, which adds manufacturing suites, formulation development laboratories, and analytical laboratories to support clinical supplies. News items also describe geographic expansion, including growth in Canada and the establishment of operations in continental Europe through acquisitions and leadership appointments.
The news feed includes acquisition announcements, such as the purchase of Nucro-Technics Inc. and related entities in Canada and the acquisition of bioanalytical and DMPK businesses from Accelera S.r.l. in Italy. These stories provide insight into how Frontage broadens its service offerings in analytical chemistry, microbiology, toxicology, bioanalysis, DMPK, and related areas.
Other updates focus on strategic collaborations and clinical research support, for example partnerships aimed at addressing drug development challenges in specific markets or supporting early-phase clinical trials. Leadership and organizational news, including executive appointments and role changes, offer context on how Frontage structures its management to oversee operations in regions such as Asia Pacific and Canada.
Investors, clients, and researchers can use this page to follow Frontage’s corporate actions, service expansions, and participation in notable clinical programs, as well as its recognition through CRO Leadership Awards and similar industry accolades.
Frontage Holdings Corporation (OTC:FTHCY) has announced the appointment of Dr. Abdul Mutlib as President of Frontage Laboratories, Canada, marking a strategic expansion of its services in the Canadian market. Dr. Mutlib, who will continue his role as Chief Scientific & Strategy Officer, will oversee operations in Toronto and Vancouver, reporting to Co-CEO Dr. Wentao Zhang.
With over 35 years of R&D experience in pharmaceutical and CRO sectors, Dr. Mutlib will focus on establishing Frontage as a key partner for Canada's growing biotech industry. The appointment aligns with Frontage's strategy to enhance its position as a leading global pharmaceutical Contract Research Organization (CRO).
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Frontage Holdings Corporation has announced the promotions of Dr. Abdul Mutlib to CEO and Dr. John Lin to President as of January 3, 2023. Dr. Mutlib has over 12 years of experience with Frontage, leading the Preclinical business, while Dr. Lin has been with the company for over 15 years, focusing on Bioanalytical and Biologics services. Founder Dr. Song Li remains Executive Chairman, emphasizing a focus on strategic growth. The leadership changes aim to enhance operational performance and prepare for future expansion, leveraging their extensive industry experience.
Frontage Laboratories announced a collaboration with Eisai and Biogen to support the bioanalysis of lecanemab (BAN2401) in a phase 3 study for Alzheimer's disease.
The study met aggressive timelines, showcasing Frontage's commitment to addressing medical needs. Notably, the study has delivered favorable results as highlighted in a presentation on November 29, 2022.
Frontage's scientific team contributed to biomarker analysis, reinforcing their role in global clinical research.